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180-kD bullous pemphigoid antigen (BP180) is
deficient in generalized atrophic benign
epidermolysis bullosa.
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Generalized atrophic benign epidermolysis bullosa (GABEB) is a form of nonlethal
junctional epidermolysis bullosa characterized by universal alopecia and atrophy of the
skin. We report a deficiency of the 180-kD bullous pemphigoid antigen in three patients with
GABEB from unrelated families. We screened specimens of clinically normal skin from nine
junctional epidermolysis bullosa patients (3 GABEB, 4 lethal, 1 cicatricial, 1 pretibial) by
immunofluorescence using monoclonal antibodies to the 180-kD and 230-kD bullous
pemphigoid antigens (BP180 and BP230). In the skin of the three GABEB patients there
was no reactivity with antibodies to BP180, whereas staining for BP230 was normal. In the
skin of the other six, non-GABEB patients, included in this study the expression of BP180
and BP230 was normal. Immunoblot analysis of cultured keratinocytes from one of the
GABEB patients also failed to detect BP180 antigen, whereas BP230 was present in
normal amounts. The deficient expression of BP180 is reflected in the RNA message, as in
Northern blot analysis a reduced amount of BP180 transcripts, although of normal length,
were detected. Interestingly, in another GABEB patient there were not-involved areas of
skin, in which blistering could not be induced by rubbing. Biopsy material from these areas
showed interrupted staining for BP180. There was no staining for BP180 in areas of
clinically normal but involved skin of this patient. […]
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Abstract Introduction
Generalized atrophic benign epidermolysis bullosa (GA-
BEB) is a form of nonlethal junctional epidermolysis bullosa
characterized by universal alopecia and atrophy of the skin.
We report a deficiency of the 180-kD bullous pemphigoid
antigen in three patients with GABEB from unrelated fami-
lies. We screened specimens of clinically normal skin from
nine junctional epidermolysis bullosa patients (3 GABEB,
4 lethal, 1 cicatricial, 1 pretibial) by immunofluorescence
using monoclonal antibodies to the 180-kD and 230-kD bul-
lous pemphigoid antigens (BP180 and BP230). In the skin
of the three GABEB patients there was no reactivity with
antibodies to BP180, whereas staining for BP230 was nor-
mal. In the skin of the other six, non-GABEB patients, in-
cluded in this study the expression of BP180 and BP230
was normal. Immunoblot analysis of cultured keratinocytes
from one of the GABEB patients also failed to detect BP180
antigen, whereas BP230 was present in normal amounts.
The deficient expression of BP180 is reflected in the RNA
message, as in Northern blot analysis a reduced amount of
BP180 transcripts, although of normal length, were de-
tected. Interestingly, in another GABEB patient there were
not-involved areas of skin, in which blistering could not be
induced by rubbing. Biopsy material from these areas
showed interrupted staining for BP180. There was no stain-
ing for BP180 in areas of clinically normal but involved skin
of this patient.
In conclusion, this study reveals that the BP180 antigen
is deficient and the BP180 mRNA is reduced in generalized
atrophic benign epidermolysis bullosa. (J. Clin. Invest. 1995.
95:1345-1352.) Key words: junctional epidermolysis bul-
losa * basement membrane * adhesion molecule * type XVII
collagen * immunofluorescence
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1. Abbreviations used in this paper: BP180, 180-kD bullous pemphigoid
antigen; BP230, 230-kD bullous pemphigoid antigen; BP, bullous pem-
phigoid; EB, epidermolysis bullosa; EBMZ, epidermal basement mem-
brane zone; GABEB, generalized atrophic benign epidermolysis bullosa;
JEB, junctional epidermolysis bullosa.
The 180-kD bullous pemphigoid antigen (BPl80)' is a putative
cell-matrix adhesion molecule and is restricted to hemidesmo-
somes of stratified squamous epithelia. It is possibly involved
in junctional epidermolysis bullosa (JEB), in which hemides-
mosomes have been found to be abnormal (1). Unlike the 230-
kD bullous pemphigoid antigen (BP230), BP180 appeared to
have both intracellular and extracellular domains (2, 3), which
is in agreement with the deduced amino acid sequence of the
cloned BP180 cDNA (4). Because BP180 is a transmembrane
glycoprotein (3), it might be involved in those forms of JEB,
in which, until now, no molecular abnormality has been re-
vealed. In contrast, BP230 is localized entirely intracellularly
(2) and is thus less likely to be involved in JEB, in which the
split level occurs in the lamina lucida. Stanley and co-workers
found no gross abnormalities of the BP230 gene in patients
with lethal or non-lethal JEB (5). Molecular genetic studies of
BP180 in JEB patients have not yet been performed.
In previous studies on the expression of the bullous pemphi-
goid antigen in JEB, sera from bullous pemphigoid (BP) pa-
tients were used, the specificity of which had not been analyzed
by immunoblotting (6-9). The expression was found to be
normal or variable. Later it became apparent that BP-serum is
a mixture of polyclonal antibodies, which are very difficult to
characterize, even after affinity-purification (10). Fortunately,
reliable monospecific antibodies for each of the two major bul-
lous pemphigoid antigens have now become available (1 1, 12).
In this study we used monoclonal antibodies specific for
BPI 80 and BP230 (11, 12). In addition we studied the expres-
sion of the newly described 500-kD hemidesmosomal plaque
protein HD1 (13) in our series of JEB patients. We found a
deficiency of the BP180 protein in patients with generalized
atrophic benign epidermolysis bullosa (GABEB). The Northem
blot analysis of cultured keratinocytes of one patient showed a
reduced amount of BP180 mRNA of normal size. BP230 and
HDI were normally present in the GABEB patients.
Generalized JEB mitis is acknowledged by an intemational
consensus committee to be a distinct form of JEB (14), dif-
fering from Herlitz disease (generalized JEB gravis) by its ab-
sence of anemia and growth retardation. The category general-
ized JEB mitis has not yet been split into subtypes and is also
referred to as generalized atrophic benign epidermolysis bullosa
(GABEB) (15), epidermolysis bullosa atrophicans generalisata
mitis ( 16) and nonlethal JEB ( 17) or non-Herlitz JEB. The first
kindred with GABEB was described in 1976 by Hashimoto,
Schnyder and Anton-Lamprecht and named Disentis type
(McKusick #22665), to the place of birth of the patients (18).
The term GABEB and the clinical entity: nonlethal JEB with
atrophic skin and alopecia, was introduced in 1982 by Hintner
BPJ80 and Junctional EB 1345
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Table 1. Summary of the Examined Antibodies to BP180, BP230, and HDJ
Antigen Antibody Gift from, reference Antigen source Antibody (iso)type Antibody source Titer used
BP180 ec* IDI Ref. 3 Bovine cornea mo IgGI Mouse 50
BP180 ict lA8c Ref. 3 Bovine cornea mo IgGI Mouse 30
BP180 ec R306.3 Giudice, 20 Recombinant BP180 po IgG Rabbit 50
BP180 S2204 This study Human skin po serum Human 80
BP230 R815 Ref. 11 Rat keratinocytes mo IgGI Mouse 50
BP230 SE Hashimoto, 12 Human skin mo IgG2 Human 50
BP230 IOD Hashimoto, 12 Human skin mo IgG2 Human 50
BP230/180 S3105 This study Human skin po serum Human 80
HD1 HD121 Ref. 13 Bovine cornea mo IgGI Mouse 50
* ec, extracellular domain; * ic, intracellular domain.
and Wolf (15). The clinical features of GABEB are continuous
blistering since birth, cigarette paper-like atrophic depigmented
skin at sites of recurrent blistering (no scarring or milia), nor-
mal growth and lack of anemia, moderate improvement during
aging, dystrophic nails and dentition, mild mucous membrane
involvement, and according to Hintner and Wolf ( 15 ), a typical
pattem baldness with significant scalp atrophy, partial absence
of eyelashes and eyebrows, and absence of pubic and axillary
hair.
Methods
Patients. Three JEB cases with clinical GABEB phenotype from, ac-
cording to the patients, unrelated families were included: a 40-yr-old
male (No. 1), product of a consanguineous marriage, a 42-yr-old female
(No.2) and a 27-yr-old female (No.3) both products of nonconsanguin-
eous marriages. All three patients had affected siblings. Patient 1 had
undergone allogeneic kidney transplantation because of renal failure of
unknown origin.
Six other JEB patients were examined: three patients with GB3-
negative lethal JEB (No. 4-6), one patient with GB3-positive lethal
JEB (No. 7), one patient with cicatricial JEB (No. 8) (19), and one
patient with localized pretibial JEB (No. 9). In addition we examined
six patients with epidermolysis bullosa simplex (4 generalized and 2
localized EBS) to control for a possible aspecific variability of bullous
pemphigoid antigen expression (6). Diagnosis was established in each
patient on the basis of clinical findings, family history, immunofluores-
cence antigen mapping, and electron microscopy. Patients 4 and 5 with
GB3-negative lethal JEB showed cytoplasmic redistribution of the a6,f4
integrin in the absence of laminin-5, which we have published in a
previous report (27).
Skin specimens. 4-mm punch biopsies were obtained from clinically
normal skin of the flexor aspect of the upper arm of the patients. In the
GABEB patients multiple skin biopsies were taken from various other
parts of the body. We also obtained biopsies of clinically normal skin
after inducing subclinical blistering by gently rubbing with a thumb.
Skin specimens from healthy adults served as control tissues. The skin
specimens were snap frozen for immunofluorescence or fixed with 2%
glutaraldehyde for electron microscopy.
Source ofantibodies. Characteristics of the antibodies used are sum-
marized in Table I. Monoclonal antibodies IDI, lA8c, and HD121,
raised against the hemidesmosome-enriched fraction of the Bowman's
membrane of bovine corneae, and R815 against rat keratinocytes have
been described (3, 11, 13). The affinity-purified rabbit serum R306.3
( =RNDla) raised against a recombinant extracellular domain of human
BP180 (coding nucleotides 1624-1995 and 2593-2670) was a gener-
ous gift of Dr. G.J. Giudice (20). The specificity of antibodies was
established by immunoblot on extracts of normal human keratinocytes
(this study: lA8c) and of the human carcinoma cell line A431 (3, 11).
Monoclonal antibodies 5E and IOD, derived from an immortalized B
cell line from a bullous pemphigoid patient, were a gift of Dr. Hashimoto
(12). Monoclonal antibody GB3 against laminin-5 (nicein, kalinin, epi-
ligrin) was provided through the courtesy of Dr. J.-P. Ortonne (21) and
LH7:2 against collagen type VII was a gift of Dr. I. Leigh (22). In
addition we used sera from bullous pemphigoid patients that recognizes
both the 180- and 230-kD bands in the immunoblot (S3105, titer 1:640)
(see Fig. 6, lane a) or only the 180-kD antigen (S2204). The a6 integrin
subunit was stained with our moabs GoH3 (23) or J8H (24) and the
,64 integrin subunit with moabs 439-9B or 4.3E1, gifts of Dr. S.J.
Kennell (25) and Dr. E. Engvall (26), respectively.
In combination with primary mouse monoclonal antibodies we used
biotinylated horse anti-mouse IgG (Vector Laboratories, Inc., Bur-
lingame, CA) and DTAF (dichlorotriazinyl-amino-fluorescein)-conju-
gated streptavidin (Jackson ImmunoResearch, Inc., West Grove, PA)
as secondary and tertiary steps. In combination with primary human
antibodies we used mouse anti-human IgG (Southern Biotechnology
Associates [SBA], Inc., Birmingham, AL) and FITC-conjugated goat
anti-mouse IgG (Becton Dickinson, San Jose, CA). For double immu-
nofluorescence with primary moabs of murine (lD1) and rat (439-9B)
species we used goat anti-mouse IgG (SBA) and FITC-conjugated
goat anti-rat IgG (SBA) and LRSC (lissamine rhodamine)-conjugated
streptavidin (Jackson ImmunoResearch, Inc.) as secondary and tertiary
steps.
Immunofluorescence procedures. 4-,um cryostat sections of skin
specimens were processed for immunofluorescence as previously de-
scribed (27). Fluorescence overlay antigen mapping was performed as
recently described (27, 28). Digital video microscopic images of tissue
sections were obtained with a newly developed imaging system with
long exposure times designed for the detection of very low levels of
fluorescence (29).
For immunofluorescence microscopy on cells, keratinocytes were
resuspended and seeded onto coverslips in keratinocytes medium
(DME-F12/HAM 2:1, 20% FCS, 0.4 ,g/ml hydrocortisone, 10 ng/ml
EGF, 10 itg/ml non-essential amino acids and 10-10 choleratoxin) for
2-4 d. Cells were fixed with 1% formaldehyde in PBS for 10 min and
permeabilized with 0.5% Triton X-100 for 5 min at room temperature.
After rinsing and blocking in 1% BSA in PBS for 20 min, the permeabil-
ized cells were incubated with primary antibody for 30 min at 37°C.
The cells were stained and washed as described for the tissues. The
coverslips were viewed under a Nikon microscope extended with a
confocal scanning laser microscope (MRC-600, Biorad, UK).
Electron microscopy. For electron microscopy routine procedures
were followed as previously described (27).
Cell culture. From GABEB patient 1 a punch biopsy (diameter 6
mm) of involved skin of the upper arm was taken. Epidermal cells were
cultured according to a modified procedure of Rheinwald and Green
(30). Briefly, epidermal cells were dissociated from the tissue specimen
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by a 30-min incubation with trypsin and grown in two 25-cm2 culture
flasks on a monolayer of lethally irradiated 3T3-mouse fibroblasts in
keratinocytes medium (DME-F12/HAM 2:1, 20% FCS, 0.4 Mg/ml hy-
drocortisone, 10 ng/ml EGF, 10 ,ug/ml non-essential amino acids and
10`-0 choleratoxin).
Immunoblot procedure. At subconfluence cultured keratinocytes
were lysed by overlaying them with demineralized water. The lysis
liquid was discarded and the remaining cellular constituents solubilized
with SDS-PAGE denaturation buffer (10 mM Tris-HCl, pH 6.8 con-
taining 1 mM EDTA, 2.5% SDS, 5% 2-mercaptoethanol, and 10%
glycerol). Samples were heated for 10 min at 100°C and centrifuged at
14,000 g for 15 min. The supernatant was collected and stored at -80°C
until used for immunoblot. Control cultures of normal keratinocytes
from tissue obtained by breast reduction served as control. SDS-PAGE
was performed according to Laemmli (31), using 5% slab gels in the
BioRad Mini Protean II electrophoresis apparatus (BioRad Laboratories,
Richmond, CA). After separation the gel was blotted to nitrocellulose
using the Mini Protean II blotting unit. After transfer the nitrocellulose
was blocked with TTBS-buffer (20 mM Tris-HCl pH 7.5, 500 mM
NaCl, 0.05% Tween-20) and incubated with 1:300 diluted serum S3105
and 1:100 diluted monoclonal antibodies lA8c and SE.
In combination with primary human antibodies we used affinity
purified mouse anti-human IgG, Fc-fragment specific (Jackson Immu-
noResearch, Inc.) and blotting grade affinity purified alkaline phospha-
tase conjugated goat anti-mouse IgG (BioRad), as secondary and ter-
tiary steps. In combination with primary mouse antibodies we used goat
anti-mouse IgG (Jackson ImmunoResearch, Inc.) followed by alka-
line phosphatase conjugated rabbit anti-goat IgG (Jackson ImmunoRe-
search, Inc.).
Northern blot analysis. Total RNA was isolated from cultured kera-
tinocytes of patient 1, normal human keratinocytes and from the squa-
mous cell carcinoma cell line UMSCC-22B using ULTRASPEC RNA
reagent (Biotex lab., Inc., Houston, TX), separated on a 1% agarose
gel containing 6% formaidehyde and transferred to nitrocellulose by a
standard procedure (32). The nitrocellulose filter was hybridized for 16
h at 420C with 32P-labeled cDNA probes in 50% formamide, 5x SSC,
50 mM NaH2PO4, pH 6.8, 0.1% SDS, 100 ,ug herring sperm DNA
and 2x Denhardt's solution (lx = 0.02% polyvinylpyrrolidone, 0.02%
Ficoll and 0.02% bovine serum albumin). The filters were washed two
times with 2x SSC/0.1% SDS and once with lx SSC/0.1% SDS at
42°C, dried and exposed to Kodak X-OMAT AR film with intensifying
screen at -70°C. The following cDNA probes were used: (a) a 782-
kb fragment, position 1771 to 2553 (4), coding for the extracellular
part (NC16a en C15 domains) of BP180 and (b) a 700-kb fragment
coding for actin. The cDNA probes were 32P-labeled using Random
primer labelling kit (GIBCO BRL, Gaithersburg, MD).
Results
Clinical description. The three GABEB patients had all the
characteristics as summarized in the introduction (Fig. 1). The
alopecia was not limited to terminal hair but also involved vellus
hair. Mucous membranes were mildly affected: the patients oc-
casionally had red eyes, nasal blood crusts, and oral erosions
without dysphagia. Hypergranulation as in Herlitz disease was
absent. The large naevocytic naevi as reported by Hintner and
Wolf (15) in their GABEB family were not present in our
patients.
GABEB patient 3 was unique. She was the only patient who
had areas of skin with normal adherence and normal sensibility
by touch. Examination by touching and rubbing disclosed a
symmetrical patchy distribution of these areas over the extensor
surface of the elbow, forearm, wrist, and hands (thenar and
extensor surface of index and middle finger). We could not
induce blisters after extensive rubbing in these areas. In contrast
blisters could easily be evoked in similarly looking, clinically
-7-/ t
Figure 1. Clinical appearance of generalized atrophic benign epidermol-
ysis bullosa. Typical scalp alopecia with follicular atrophy (patient 2).
normal but involved skin of the same patient. Patients 1 and 2
did not have any skin areas that were not-involved: all parts of
the body were fragile.
Electron microscopy and immunofluorescence studies of
skin biopsy material. Electron microscopy of affected skin of
the GABEB patients revealed a split through the lamina lucida.
In specimens from clinically normal and from lesional GABEB
skin, hemidesmosomes were rudimentary and received less in-
termediate filaments than hemidesmomes from specimens from
a healthy individual (Fig. 2). Despite the hypoplastic structure,
some hemidesmosomes still possessed a subbasal dense plate.
Antigen mapping of the affected skin of the GABEB pa-
tients by immunofluorescence showed laminin-5 (GB3), lami-
nin-i and collagen type VII (LH7:2) exclusively in the blister
floor and pan-keratin CKI (Dako A/S, Glostrup, Denmark)
exclusively in the blister roof. Immunofluorescence of clinically
normal skin with monoclonal antibodies to laminin-5 and the
a6,64 integrin gave normal results, as previously published for
patient 1 (27).
The immunofluorescence results with skin tissues are sum-
marized in Table II. There was no binding of moab lD1 in the
epidermal basement membrane zone (EBMZ) in the clinically
normal, involved skin from the upper arm of the GABEB pa-
tients (Fig. 3 A). In specimens from areas of not-involved skin
of GABEB patient 3, unreduced staining with lDI occurred in
patches along the EBMZ making up - 50% of the total length
BPI80 and Junctional EB 1347
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Figure 2. Electron micrographs of skin of a normal individual (A) and of clinically normal skin of GABEB patient 1 (B). Hemidesmosomes are
rudimentary in GABEB (B) and receive less intermediate filaments than normal hemidesmosomes (A). Subbasal dense plates (arrows) are still
present in GABEB hemidesmosomes. Bars, 100 nm.
and interrupted by patches of 50-100 ,um long in which no
staining occurred (Fig. 4 A). Staining for other basement mem-
brane components like integrin a6f64 (Fig. 4 B), HD- 1, laminin-
1 and laminin-5 showed a normal continuous pattern at these
sites (data not shown). However, the 1 80-kD antigen was unde-
tectable in the clinically normal, involved skin and in involved
skin from the same patient. In all the non-GABEB patients
binding of lDI was normal, similar to controls.
Binding of moab lA8c directed against the intracellular
domain of BP180 did not occur in the specimens of the GABEB
patients (Fig. 3B), nor was there reactivity with the polyclonal
antibody R306.3 against an extracellular BPI 80 epitope (Fig.
3C). In specimens from not-involved skin of patient 3 the stain-
ing patterns of lA8c and R306.3 were similarly interrupted as
with moab IDI.
Also binding of moab R815 to BP230 was normal in all
GABEB specimens (Fig. 3 D). The other JEB specimens,
stained also normally with antibodies to BP230, and with BP-
serum (S3105). The presence of BP230 in GABEB skin was
confirmed with moabs SE and I OD both producing an unreduced
linear pattern. BP230 was consistently found in the blister roofs
in GABEB specimens. Binding of moab HD-121 to 500-kD
HDl plaque protein was normal in all JEB skin samples studied
(data not shown).
We checked for variable BP antigen binding, as was found
by Fine et al. (6) in the skin of patients with EB simplex
using polyclonal BP-sera. However, in all six patients whom
we studied, the reactivity with monoclonal antibodies IDl and
R815 appeared to be normal.
Immunofluorescence and immunoblot studies of cultured
keratinocytes. Immunofluorescence of cultured keratinocytes
from patient 1 IDI (Fig. 5 A), lA8c and S2204 was negative.
Nevertheless, the other hemidesmosomal components 500-kD
HD 1, a6 and /34 (Fig. 5 B) were distributed in the normal
pattern of dotted tracks which is characteristic for hemidesmo-
somal components.
To further confirm the absence of BP180, immunoblotting
on extracts of cultured keratinocytes from GABEB patient 1
Table II. Epidermal Basement Membrane Zone Staining with Antibodies against Laminini-5, BP230 and HDI in Clinically Normal Skin
of Patients with Junctional Epidermolysis Bullosa
GB3 IDI lA8c R306.3 S2204 R815 5E IOD
Patient No. Patient laminin-5 BP180ec BP180ic BP180ec BP180 BP230 BP230 BP230
0 Human controls + + + + + + + +
1 GABEB + - - - - + + +
2 GABEB + - - - - + nd nd
3 GABEB + -* -* -* -* + nd nd
4 Lethal JEB - + nd nd nd + nd nd
5 Lethal JEB - + nd nd nd + nd nd
6 Lethal JEB - + nd nd nd + nd nd
7 Lethal JEB + + nd nd nd + nd nd
8 Cicatricial JEB + + nd nd nd + nd nd
9 Pretibial JEB + + nd nd nd + nd nd
+, Uniformly present; -, absent; and nd, not done. * Absent in clinically normal, involved skin, focally present in not-involved skin areas.
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Figure 3. Immunofluorescence of clinically normal skin from GABEB patient 1 (A-D) and of control skin (E-H) using antibodies lDl (A and
E), lA8c (B and F), and R306.3 (C and G) to BP180 and R815 (D and H) to BP230. Antibodies to BP180 did not react with GABEB skin (A-
C), whereas antibody to BP230 produced normal staining (D). (Bar, 10 pm).
was performed. BP180 was not detected with monoclonal anti-
body 1A8c and the 180-kD band was absent, when BP-serum
S3105, which recognizes both BP230 and BP180 in control
keratinocyte extracts was used (Fig. 6). The 230-kD bullous
pemphigoid antigen was demonstrable by immunoblot in skin-
extracts of the GABEB patient. The presence of BP230 in GA-
BEB keratinocytes was confirmed with moab 5E to BP230.
Northern blot analhsis. Northern blot analysis of RNA iso-
lated from cultured keratinocytes of patients 1 showed BP180
transcripts of 6.0 and 4.9 kb (Fig. 7 A, lane 2). The size of
these transcripts is not different from those in the squamous
cell carcinoma cell line UMSCC-22B (Fig. 7 A, lane 1), and
are consistent with the sizes of the transcripts reported for
BP180 (4). In normal keratinocytes, only the 6.0-kb BP180
transcript was detected (Fig. 7 B, lane 1). The level of expres-
sion in normal keratinocytes and UMSCC-22B cells were com-
parable, whereas it was greatly reduced in the keratinocytes
from patient 1 (Fig. 7 A, lane 2). Control hybridizations with
a probe for actin showed that equal amounts of RNA are present
on the filters. Thus, the amount of BP180 mRNA was reduced
in cultured keratinocytes of the GABEB patient.
Discussion
It is shown for the first time that the BP180 molecule is involved
in the hereditary disorder: generalized atrophic benign epider-
molysis bullosa (GABEB). In our previous study we found that
the expression of the "bullous pemphigoid antigen" was not
reduced in the GABEB patient 1 of the present study (27). In
retrospect, however, we realized that we had used serum from
a patient with bullous pemphigoid, which later as shown in the
immunoblot appeared to contain in addition to antibodies to
BP180, antibodies to the 230-kD bullous pemphigoid antigen.
Therefore, the deficiency of BP180 could not be detected by
this serum. The use of monoclonal antibodies specific for the
two distinct BP antigens has now revealed this deficiency.
Figure 4. Fluorescence overlay antigen mapping (C) of a skin section from clinically normal not-involved skin of GABEB patient 3 using moabs
IDI to BP180 (A) and 439-9B to the integrin ,34 subunit (B). BP180 (A) is interrupted along the epidermal basement membrane on stretches
between 50-100 pm long, while the ,34 subunit (B) is continuously present in the same section. The overlay image (C) of A and B shows yellow
fluorescence on sites where both antigens are present (between arrovts). The absence of BP180 cannot be attributed to artifact or sequelae of
blistering. (Bar, 50 pm).
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Figure 5. Immunofluorescence of cultured keratinocytes in vitro from
GABEB patient 1 (A and B) and control (C and D) stained with moab
lDi to BP180 (A and C) and moab 4.3E1 to integrin ,/4 (B and D).
GABEB keratinocytes do not express BP180, but staining for the inte-
grin ,l4 shows the normal pattern of dotted arrays representing stable
anchoring complexes. (Bar, 25 prm).
The failure of antibody binding to BP180 in the GABEB
patients is not restricted to one anatomical site since results
with biopsies from alternative involved but clinically normal
sites were identical. BP180 could also not be detected by immu-
nofluorescence or immunoblot in keratinocytes cultured under
standard conditions. However, in areas of not-involved, clini-
cally normal skin from patient 3, BP180 was interrupted along
BP230--
BP180-
1 2 3 4 5 6 7 8 9
Figure 6. Immunoblot of extracts of cultured keratinocytes from control
(lanes 1-3), from GABEB patient 1 (lanes 4-6), and from mouse
fibroblasts (lanes 7-9) using BP-serum S3105 (lanes 1, 4, 7), moab
lA8c to BP180 (lanes 2, 5, 8) and moab SE to BP230 (lanes 3, 6, 9).
Note that in the GABEB patient BP180 is missing (lanes 4, 5) and
BP230 is present (lanes 4, 6). The mouse fibroblasts were included for
control on irradiated 3T3 cells used in keratinocyte cultures.
2.1- * ACTIN
1 2 1 2
Figure 7. Northern blot analysis. (A) Total RNA (10 Ag/lane) from
UMSCC-22B cells (A, lane 1) and from cultured keratinocytes of GA-
BEB patient 1 (A, lane 2) was electrophoretically separated on 1%
agarose/formaldehyde gel, transferred to nitrocellulose filter and probed
with 32P-labeled cDNA coding for BP180 and actin. The BP180 mRNA
signal is reduced, but not that of actin mRNA, in keratinocytes of the
patient. (B) Total RNA (10 tsg/lane) from normal human keratinocytes
(B, lane 1) and from UMSCC-22B cells (B, lane 2) were assayed the
same way as in A. The level of expression of BP180 mRNA in normal
keratinocytes and UMSCC-22B cells were comparable.
50% of the EBMZ, while other basement membrane compo-
nents were not interrupted (Fig. 4).
The interrupted presence of BP180 in the not-involved skin
of patient 3 is apparently sufficient to prevent skin blistering in
these areas. This patient had an affected sibling, who is deceased
and who therefore could not be studied. The BP180-positive
patches might have been present only in patient 3 and might
reflect somatic mosaicism in this patient: part of the cells es-
caped the generalized autosomal recessive disorder. This could
be the result of somatic reversion due to recombination or to a
reverse mutation of one of the two different mutations originally
present on the two separate BP180 alleles (compound heterozy-
gote), thus rendering this allele normal. If somatic reversion
did happen in a putative primordial stem cell, then the BP180-
positive patches with a diameter of 50-100 Am might reflect
the area in which the keratinocytes, supplied by divisions of
one stem cell, are localized.
The BP180 deficiency was exclusively found in the GABEB
patients and not in the other JEB patients studied. We found
no abnormal expression of the hemidesmosomal plaque proteins
BP230 or HD1 in any of the JEB patients. In the three GB3-
deficient lethal JEB patients the disease is obviously the result
of a defect in the laminin-5 genes (33). However, in the GB3-
positive lethal JEB patient (No. 7) and in the two non-lethal
JEB patients (cicatricial JEB No. 8 and localized JEB No. 9)
in this study, the molecular defect remains unknown.
The category generalized JEB mitis to which GABEB be-
longs, encompasses also nonlethal JEB patients with reduced
laminin-5 (GB3) expression (34), in which recently a homozy-
gous mutation in the LAMC2 gene have been demonstrated
(35). Our GABEB patients did not have any reduction in the
expression of laminin-5 (GB3). Thus the category generalized
JEB mitis appears to be heterogeneous and GABEB appears to
be a clinical subset characterized by alopecia. The question
whether alopecia in generalized JEB mitis is characteristic for
BP180 deficiency remains to be elucidated.





The reduced amount of normal length BP180 mRNA in
GABEB keratinocytes, as detected by Northern blot analysis,
suggests a mutation in the BP180 gene resulting in reduced
transcription or instability of the transcript. If that is the case,
the lack of BP180 antigen in GABEB is due to reduced transla-
tion or to the presence of an early premature stop codon. An
alternative hypothesis, namely that a post-translational failure
of protein processing might explain the deficiency of BP180,
is less likely because of the results of the Northern blot analysis.
Moreover, the intracellular and extracellular epitopes of BP180
were undetectable, which would be unlikely if improper post-
translational protein folding had caused the deficiency. All to-
gether the evidence supports the total absence of the BP180
antigen in skin of GABEB patients.
As to the mode of inheritance, the pedigrees of our patients
indicate a recessive form of the abnormal allele. Human BP180
has been cloned and sequenced. BP180 has interrupted collage-
nous domains in the extracellular region, which have determined
some authors to classify the molecule as type XVII collagen
(36). The gene is located on chromosome 1Oq24.3 (37). Mo-
lecular genetic studies are now in progress to further localize
and identify the specific mutation responsible for the abnor-
mality.
From this study it appears that the transmembrane molecule
BP180 is essential for cell adhesion, since the deficiency of this
molecule is associated with serious skin abnormalities. Autoim-
munity against the extracellular domain of this molecule (20),
as it occurs in bullous pemphigoid might also lead to detachment
and blistering of skin. BP180 also appears to be critical for hair
root anchorage. GABEB patients loose their terminal hair in
childhood between the age of 5 and 12. The almost complete
absence of the vellus hair should also be mentioned. Patients
never develop a secondary hair pattern in puberty, although the
gonads appear to function normally. It remains to be elucidated
why the mucous membranes in patients with GABEB are in-
volved to a lesser extent than skin, since BP180 is normally
also present along the basement membranes of the cornea, the
mouth, the ear, the nose, the throat, the esophagus and in the
urogenital tract. It is possible that the kidney failure of patient
1 is the result of lesions in the urinary tract. Renal dysfunction
has been associated with GABEB (38).
Knowing that BP180 is deficient in GABEB, the ultrastruc-
ture of the hemidesmosomes becomes significant. Notably, rudi-
mentary hemidesmosomes were present in GABEB skin, some
even possessed a subbasal dense plate (Fig. 2 B). Thus, for
hemidesmosomes to mature BP180 seems to be necessary, but
it appears not to be critical for their initial assembly. In a previ-
ous study we found no abnormality of the expression of integrin
a6/34 in GABEB (27). These findings emphasize the hypothe-
sis that integrin a6,64 (and not BP180) plays a critical role in
initial hemidesmosome assembly (39).
In conclusion, in this study we found that the BP180 antigen
is deficient and the BP180 mRNA is reduced in GABEB, sug-
gesting that BP180 gene is candidate gene for this hereditary
blistering disorder.
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